Ashish V. Joshi, PhD

This study identified inefficiencies in drug and medical service utilization related to pain management among Medicare members with osteoarthritis and chronic low back pain.

A formulary restriction policy in a Medicare population was associated with lower celecoxib utilization; however, higher gastrointestinal- and arthritis-related medical costs were observed.

Prior authorization for pregabalin in commercial insurance plans accomplished the objective of lower pregabalin utilization; however, there was no significant decrease in disease-related healthcare costs.